Millie
your market intelligence analyst
Search Results
16 results
Your search is now limited to «Ovarian Cancer» expert search.
PubMed News (NIH) 10/18/2019
Status Public on Oct 18, 2019 Title Profiling gene expression changes in ovarian cancer cells seeded on 3D organotypic culture of omentum Organism Homo sapiens Experiment type Expression profiling by high throughput sequencing Summary Ovarian cancer is the deadliest gynecologic malignancy and the fifth leading cause for cancer related ...
Purpose:. PARP inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOC). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We assessed the activity of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor known to cause replication catastrophe, as monotherapy and in combination with the PARP inhibitor olaparib in preclinical models of HGSOC, including those with acquired PARP inhibitor resistance. Experimental Design:. Prexasertib was tested as a single agent or in combination with olaparib in 14 clinically annotated and molecularly characterized luciferized HGSOC patient-derived xenograft (PDX) models and in.
Activation of ferroptosis, a recently described mechanism of regulated cell death, dramatically inhibits growth of ovarian cancer cells. Given the importance of lipid metabolism in ferroptosis and the key role of lipids in ovarian cancer, we examined the contribution to ferroptosis of stearoyl-CoA desaturase (SCD1, SCD), an enzyme that catalyzes the rate-limiting step in monounsaturated fatty acid synthesis in ovarian cancer cells. SCD1 was highly expressed in ovarian cancer tissue, cell lines, and a genetic model of ovarian cancer stem cells. Inhibition of SCD1 induced lipid oxidation and cell death. Conversely, overexpression of SCD or exogenous administration of its C16:1 and C18:1 products, palmitoleic acid or oleate, protected cells fr.
Growing epidemiologic evidence supports chronic inflammation as a mechanism of ovarian carcinogenesis. An association between a circulating marker of inflammation, C-reactive protein (CRP), and ovarian cancer risk has been consistently observed, yet, potential heterogeneity of this association by tumor and patient characteristics has not been adequately explored. In this study, we pooled data from case–control studies nested within six cohorts in the Ovarian Cancer Cohort Consortium (OC3) to examine the association between CRP and epithelial ovarian cancer risk overall, by histologic subtype and by participant characteristics. CRP concentrations were measured from prediagnosis serum or plasma in 1,091 cases and 1,951 controls. Multivariable.
One of the best pieces of advice I got before starting to treat stage III was from my oncologist, . He said it was important to continue working and spending time with my friends and family, to keep my life as normal as possible. Otherwise, I could fall into a negative mindset, which would only make my feel harder. I believe staying positive is just as important as the drugs that are administered. So, I followed his advice. And except for the days on which I had chemotherapy infusions, I worked the entire time, either from home or in the office. I also didn’t really discuss my treatment at work. It’s not that I was trying to hide it; I was very open if someone asked me about it. I just didn’t want the fact that I had cancer to be the first

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities

Sources

Strategic Scenarios

Trends